Meanwhile, GEPIA database analysis showed that the long-term survival of bladder cancer patients with high expression of MCT4 was significantly lower than that of bladder cancer patients with low expression of MCT4, which suggested that MCT4 may be a potential target for bladder cancer therapy. The gene discussed is SLC16A3; the disease is urinary bladder carcinoma.